文献速递脑血管病

成人脑静脉血栓遗传易感性:候选基因研究更新荟萃分析

Genetic Susceptibility to Adult Cerebral Venous Thrombosis: An Updated Meta-Analysis of Candidate Gene Studies.
PubMed 文献 · Stroke · 2026-01-02

结果显示凝血因子V Leiden、凝血酶原G20210A、蛋白C/S及抗凝血酶遗传性缺陷、JAK-2 V617F突变均显著增加风险,而MTHFR C677T和PAI-1 4G/5G多态性无显著关联。

要点

  • 凝血酶原G20210A与成人脑静脉血栓关联最强(OR 6.05),蛋白C缺陷OR达10.30。
  • JAK-2 V617F体细胞突变亦显著增加风险(OR 9.17),提示需关注骨髓增殖性肿瘤。
  • MTHFR C677T和PAI-1 4G/5G多态性与成人脑静脉血栓无显著关联。

核心结论

  • 成人脑静脉血栓具有遗传基础,多种促血栓基因变异显著增加患病风险。
  • 遗传关联模式与儿童脑静脉血栓大致相似,但强于成人动脉性缺血性卒中。

研究设计与样本

  • 更新荟萃分析,系统检索PubMed、EMBASE和Web of Science截至2025年1月的病例对照研究。
  • 采用随机效应模型计算合并比值比(OR)及95%置信区间(CI)。

主要发现

  • 凝血因子V Leiden:患者组238/2753(8.6%) vs 对照组387/8747(4.4%),OR 2.59(95%CI 2.06-3.26),P<0.00001。
  • 凝血酶原G20210A:患者组290/2483(11.7%) vs 对照组235/8197(2.9%),OR 6.05(95%CI 4.59-7.98),P<0.00001。
  • 蛋白C遗传性缺陷:患者组24/624(3.8%) vs 对照组7/2027(0.3%),OR 10.30(95%CI 4.19-25.30),P<0.00001。
  • 蛋白S遗传性缺陷:患者组9/567(1.6%) vs 对照组1/1125(0.1%),OR 6.86(95%CI 2.12-22.24),P=0.001。
  • 抗凝血酶遗传性缺陷:患者组11/440(2.5%) vs 对照组3/989(0.3%),OR 5.73(95%CI 1.98-16.55),P=0.001;JAK-2 V617F:患者组27/569(4.7%) vs 对照组13/1777(0.7%),OR 9.17(95%CI 3.61-23.27),P<0.00001。

关键数值与推荐

  • MTHFR C677T和PAI-1 4G/5G多态性与成人脑静脉血栓无显著关联。
  • 总体效应量与儿童脑静脉血栓报道相当,但超过成人动脉性缺血性卒中的报道。

临床怎么用

  • 对成人脑静脉血栓患者可考虑选择性遗传检测(如凝血因子V Leiden、凝血酶原G20210A、蛋白C/S/抗凝血酶缺陷、JAK-2 V617F)以进行风险分层和管理。

局限性

  • 纳入研究均为病例对照设计,可能存在选择偏倚和混杂因素。
  • 原文未报告发表偏倚评估、异质性检验及敏感性分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic predisposition is increasingly recognized as an important contributor to cerebral venous thrombosis (CVT), yet findings from individual studies remain inconsistent. We conducted an updated meta-analysis to quantify associations between specific genetic variants and adult CVT. METHODS: We systematically searched PubMed, EMBASE, and Web of Science up to January 2025 for case-control studies comparing the prevalence of genetic variants in adults with CVT versus healthy controls. Pooled odds ratios (ORs) with 95% CIs were calculated using random-effects models in this meta-analysis. RESULTS: Sixty-one studies comprising 4106 patients with CVT and 12 323 controls were analyzed. Significant associations were identified for germline variants, including factor V Leiden (238/2753 [8.6%] versus 387/8747 [4.4%]; OR, 2.59 [95% CI, 2.06-3.26]; P<0.00001), prothrombin G20210A (290/2483 [11.7%] versus 235/8197 [2.9%]; OR, 6.05 [95% CI, 4.59-7.98]; P<0.00001), and inherited deficiencies of protein C (24/624 [3.8%] versus 7/2027 [0.3%]; OR, 10.30 [95% CI, 4.19-25.30]; P<0.00001), protein S (9/567 [1.6%] versus 1/1125 [0.1%]; OR, 6.86 [95% CI, 2.12-22.24]; P=0.001), and antithrombin (11/440 [2.5%] versus 3/989 [0.3%]; OR, 5.73 [95% CI, 1.98-16.55]; P=0.001). The somatic JAK-2 (Janus kinase-2) V617F mutation was likewise associated with increased risk (27/569 [4.7%] versus 13/1777 [0.7%]; OR, 9.17 [95% CI, 3.61-23.27]; P<0.00001). By contrast, MTHFR (methylenetetrahydrofolate reductase) C677T and PAI-1 (plasminogen activator inhibitor-1) 4G/5G polymorphisms showed no significant associations. Overall effect sizes were comparable to those reported in pediatric CVT but exceeded those in adult arterial ischemic stroke. CONCLUSIONS: These findings support a genetic basis for adult CVT. Risk associations are broadly similar to pediatric CVT yet stronger than those reported for adult arterial ischemic stroke, highlighting distinct patterns of genetic susceptibility in venous stroke and the potential value of selective genetic testing for risk stratification and management.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Han G, Wan S, Ji X, et al. Genetic Susceptibility to Adult Cerebral Venous Thrombosis: An Updated Meta-Analysis of Candidate Gene Studies. Stroke. 2026. PMID: 41480683. doi:10.1161/STROKEAHA.125.053704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。